NICE sticks with no for Cell Therapeutics' Pixuvri
This article was originally published in Scrip
Cell Therapeutics has two weeks to appeal against negative recommendations from NICE, the health technology appraisal body for England and Wales, on the firm's anticancer Pixuvri (pixantrone). NICE still does not believe the drug would be a cost-effective use of NHS resources.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.